// App-Quantinova.ai

600 : Phase 1 Alexander Study of AUTO3, the First CD19/22 Dual Targeting CAR T Cell Therapy, with Pembrolizumab in Patients with Relapsed/Refractory (r/r) DLBCL

Researchers

Presenter

  • Aravind Ramakrishnan

Principal Investigators

  • Connie Lee Batlevi

  • Maria A V Marzolini

  • Wendy Osborne

  • Eleni Tholouli

  • Carlos Bachier

  • Peter A. McSweeney

  • Elizabeth Budde

  • Nancy L. Bartlett

  • Yiyun Zhang

  • Muhammad Al-Hajj

  • Martin Pule

  • Simon Thomas

  • Maud Jonnaert

  • Vijay G R Peddareddigari

  • Nushmia Z Khokhar

  • Robert Chen

  • Lazaros J. Lekakis

Medical Centers

  • Sarah Cannon Blood Cancer Center at St. David's South Austin Medical Center, Austin, TX

  • Department of Urology, King's College Hospital NHS Foundation Trust, London, United Kingdom

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Bart's Cancer Institute, London, United Kingdom

  • Department of Biochemistry, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom

  • Department of Haematology, Leicester Royal Infirmary, Leicester, United Kingdom

  • Texas Transplant Institute, Nashville, TN

  • Colorado Blood Cancer Institute, Presbyterian/St. Luke's Medical Center, Denver, CO

  • Washington University School of Medicine and Siteman Cancer Center, St. Louis, MO

  • Autolus Therapeutics, London, NJ, United Kingdom

  • Dolon Ltd, London, United Kingdom

  • Autolus Therapeutics, Basel, Switzerland

  • Autolus Limited, London, United Kingdom

  • Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL

Locations

  • United States

  • United Kingdom

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Diffuse large B-cell lymphoma

Biomarkers

  • Coxsackie Virus And Adenovirus Receptor

Drug/Treatment

  • Pembrolizumab

Outcome

  • N/A


Study Design

  • Cohort

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A